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Introduction
Familial Mediterranean Fever (FMF) is an autoinflamma-
tory disease characterized by recurrent attacks of fever
and serositis. A relation between FMF and Ankylosing
Spondylitis (AS) has been suggested in small cohort
studies, although there is no consensus regarding the role
of HLA B27. Colchicine, the mainstay treatment in FMF,
does not improve the axial or peripheral symptoms due to
spondylarthropathy. There are controversial data about
the efficacy of Tumor Necrosis Factor Alpha (TNF a)
blockade in FMF patients [1].
Case Report
We report our experience in 4 patients with intractable
FMF treated with oral colchicine and supplemental weekly
IV colchicine [2], that were treated with TNF a blockade
for symptomatic axial spondylarthropathy.
One 26 years old man with MEFV mutations V726A
and E148Q, negative for HLAB27, with concomitant
ulcerative colitis was treated with infliximab and then with
adalimumab; and 3 women (42, 48 and 55 years old),
two of them treated with Infliximab and one treated with
adalimumab. Two of the women were homozygous for the
M694V mutation. All developed severe to moderate
adverse events: exacerbation of FMF in 2 of them, myositis
and ulcerative colitis exacerbation in the male patient, and
staphylococcus aureus sepsis in another patient. Three of
them had to stop the TNF a blockade treatment. One
patient developed psoriatic rash, with no need to stop the
treatment.
Discussion
In our limited experience, TNF a blockade in patients
with both intractable FMF and AS is not very effective and
may be associated with severe adverse events. Little is
known about the possible interaction between intravenous
colchicine and anti-TNF treatment.
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